Login
$SER
$1.42 +$0.00 (0.0%) After hours

$SER SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2

12 Nov 2026 10-Q
03 Nov 2026 SCHEDULE 13G/A
09 Oct 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

State of Delaware Secretary of State Division of Corporations Delh•ered 12 :22 P:\1 10/05/2026 FILED 12:22 PM 10/05/2026 SR 20264597278 - File Number 6241730 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF SERINA TH...

09 Sep 2026 8-K: Other Events

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

31 Aug 2026 EFFECT
27 Aug 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

On August 21, 2026, Serina Therapeutics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as of A...

24 Aug 2026 S-1
13 Aug 2026 S-8
13 Aug 2026 8-K: Results of Operations and Financial Condition

–Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 -

13 Aug 2026 10-Q
23 Jul 2026 Form 4: Simon Farrell, Director

Granted 30,500 Stock Option (right to buy)

23 Jul 2026 Form 3: Simon Farrell, Director

No securities owned

23 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of the 19th day of July, 2026 (the “Restatement Date”), by and between (i) Serina Therapeutics, Inc., a Delaware corporation (“Serina...

22 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

HUNTSVILLE, Ala., July 22, 2026, (GLOBE NEWSWIRE) – Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, ...

22 Jul 2026 SCHEDULE 13D/A
09 Jul 2026 Form 4: Brannan Stephen K., Director

Bought 1,000 shares ($2.03K)

24 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

THIS AMENDMENT TO THE SERINA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN (this “Amendment”) is effective as of June 17, 2026. Capitalized terms used and not defined herein shall have the meanings ascribed to them in the Plan (as define...

22 Jun 2026 Form 4: Venkatesan Jay, Director

Bought 589 shares ($1.05K) · Received 224,152 shares by conversion ($504K) · Granted 15,250 Stock Option (right to buy)

22 Jun 2026 Form 4: Bailey Gregory, Director

Received 8,437,472 shares by conversion ($19M) · Granted 15,250 Stock Option (right to buy) · Granted 3,333,333 Redeemable Warrants

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support